Anti-Cytochrome P450 17A1/CYP17A1 Antibody Picoband® Fluoro647 Conjugated

Cytochrome P450 17A1, also called steroid 17α-monooxygenase, is an enzyme of the hydroxylase type that in humans is encoded by the CYP17A1 gene on chromosome 10. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. It has both 17alpha-hydroxylase and 17,20-lyase activities and is a key enzyme in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens. Mutations in this gene are associated with isolated steroid-17 alpha-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism, and adrenal hyperplasia.

Steroid 17-alpha-hydroxylase/17,20 lyase;1.14.14.19 ;17-alpha-hydroxyprogesterone aldolase;4.1.2.30 ; CYPXVII; Cytochrome P450 17A1; Cytochrome P450-C17; Cytochrome P450c17; Steroid 17-alpha-monooxygenase; CYP17A1; CYP17, S17AH

A synthetic peptide corresponding to a sequence at the C-terminus of human CYP17A1, different from the related mouse and rat sequences by ten amino acids.

Cancer, Cancer Metabolism, Cardiovascular, Cytochromes, Endocrine Metabolism, Growth Factors, Growth Factors/Hormones, Hormone Biosynthesis, Lipases, Lipid and Lipoprotein Metabolism, Lipid Metabolism, Lipids/Lipoproteins, Metabolic Signaling Pathway, Metabolic Signaling Pathways, Metabolism, Metabolism of Lipids and Lipoproteins, Mitochondrial Metabolism, Pathways and Processes, Signal Transduction

Conversion of pregnenolone and progesterone to their 17- alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty. .

1. DeVore NM, Scott EE (February 2012) . Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature. 482 (7383) : 116–9. 2. Estrada DF, Laurence JS, Scott EE (February 2016) . Cytochrome P450 17A1 Interactions with the FMN Domain of Its Reductase as Characterized by NMR. The Journal of Biological Chemistry. 291 (8) : 3990–4003. 3. Petrunak EM, DeVore NM, Porubsky PR, Scott EE (November 2014) . Structures of human steroidogenic cytochrome P450 17A1 with substrates.The Journal of Biological Chemistry. 289 (47) : 32952–64.